Pozen completes MT 100 Phase III migraine studies

POZN completed a seven-month Phase III study of 2,500 migraine patients comparing its MT 100 oral combination of the NSAID naproxen plus the anti-nausea drug metoclopramide to the two components given separately. The company also completed an open-label Phase III long term safety study in which more than 500 patients received MT 100 for six months and more than 200 patients received the product for one year. Data from the two studies are expected in the first quarter of 2001, and an NDA submission is expected by the end of 2001. ...